

Appl. Serial No.: 10/661,804

IN THE CLAIMS:

1-11. (Canceled)

12. (Currently Amended) A method to identify, monitor and/or remove CD4⁺CD25⁺ T cells from human blood and ~~other tissues ex vivo or in vivo, which method comprises;~~ comprising the step of contacting the human blood with

~~(a) —utilizing agents/ligands specifically binding to the CD4, and/or CD25, and/or CTL-A4 (CD154) entities on the T cells, preferably anti-CD4 and/or anti-CD25, and/or anti-CTL-A4 antibodies;~~

~~(b) —utilizing immunoadsorption methods; and/or~~

~~(c) —utilizing a stimulating agent or antigen presenting cells as defined in claim 4~~

whereby CD4⁺ CD25⁺ T cells are identified, monitored, and/or removed from the human blood.

13-23. (Canceled)

Please add the following new claims:

24. (New) The method of claim 12, wherein said ligands specifically binding to the CD4 and/or CD25 and/or TL-4A entities on the T cells are anti-CD4 antibodies or anti-CD25 antibodies and/or anti-CTL-A4 antibodies.

25. (New) The method of claim 12, whereby CD4⁺ CD25⁺ T cells are removed from the human blood.

26. (New) The method of claim 12, wherein said method further comprises utilizing immunoadsorption methods.

27. (New) The method of claim 12, wherein said method further comprises utilizing a stimulating agent or antigen presenting cells.

Appl. Serial No.: 10/661,804

RESTRICTION PRESENTED

The claims have been restricted into the following groups of inventions:

<u>Groups</u>	<u>Claims</u>	<u>Subject Matter</u>
I	1-3,8-10, 19 and 20	Suppressive and/or regulative CD4+CD25+T cells.
II	4-7	A method for expanding CD4+CD25+T cells.
III	11	A method of use CD4+CD25+T cells for preparing a regulatory medicament.
IV	12	A method to identify, monitor, or remove CD4+CD25+T cells from human blood and other tissue by using a binding agent, a stimulating agent or immunoadsorption method.
V	13,15, 22 and 23	Methods of using T cells stimulating agent or antigen presenting cells for preparing an agent to treating diseases with enhanced immunity.
VI	14	A method of using CD4+CD25+ cells for identifying a number of other molecules.
VII	16	A method for adoptive transfer therapy by introducing enriched regulatory CD4+CD25+ back to the patients.
VIII	17 and 18	A method of preparing CD4+CD25+ T cells with a particular desired antigen- specific T cell receptor by activating said T cell with antigen presenting cells or using a ligand/antibody to a T